探讨急性髓系白血病（AML）患者DCAG方案化疗后血清同源框A9（HOXA9）、可溶性E钙粘蛋白（SE-CAD）和Ⅲ型前胶原（PCⅢ）水平的变化及其与预后的关系。回顾性分析2018年3月至2021年12月在我院诊治的80例复发/难治性AML患者的资料。根据治疗方案的不同，将患者分为DCAG组（n=40）和CAG组（n=40）。比较临床疗效及治疗前后HOXA9、SE-CAD、PCⅢ水平的变化。此外，根据临床疗效将所有患者分为缓解组（n=58）和非缓解组（n=22）。通过单因素和多因素分析来分析影响AML患者预后的危险因素。分析HOXA9、SE-CAD、PCⅢ三项单项指标及其组合对预后的预​​测效能。与治疗前比较,DCAG组和CAG组HOXA9、SE-CAD、PCⅢ水平均升高。治疗后各项指标改善情况及临床疗效均明显优于CAG组（均P < 0.05）。多因素分析显示，骨髓母细胞计数、HOXA9 mRNA、SE-CAD、PCⅢ水平升高是影响AML患者化疗疗效的独立危险因素（均P < 0.05）。 ROC曲线显示HOXA9 mRNA、SE-CAD和PCIII联合能有效预测AML患者的预后，敏感性为84.80%，特异性为88.20%。DCAG方案可显着提高HOXA9 mRNA、SE-CAD水平AML患者的CAD和PCⅢ，这三项指标都是影响AML患者预后的独立危险因素，三项指标联合可以有效预测患者的预后。

To investigate the changes in serum homeobox A9 (HOXA9 ), soluble E-cadherin (SE-CAD) and type Ⅲ procollagen (PCⅢ) levels in acute myeloid leukemia (AML) patients after chemotherapy with DCAG regimen and their relationship with prognosis.The clinical data of 80 patients with relapsed/refractory AML diagnosed and treated in our hospital from March 2018 to December 2021 were retrospectively analyzed. According to different treatment regimen, the patients were divided into DCAG group (n=40) and CAG group (n=40). The clinical efficacy and changes of HOXA9 , SE-CAD and PCⅢ levels before and after treatment were compared. In addition, all patients were divided into remission group (n=58) and non-remission group (n=22) according to the clinical efficacy. Univariate and multivariate analyses were performed to analyze the risk factors affecting the prognosis of AML patients. The predictive efficacy of the three single indicators, HOXA9 , SE-CAD, and PC III, and their combination on prognosis was analyzed.Compared with before treatment, the levels of HOXA9 , SE-CAD and PCⅢ in both the DCAG and CAG groups were decreased after treatment, and the improvement of each indicator and the clinical efficacy in the DCAG group were significantly better than those in the CAG group (all P < 0.05). Multivariate analysis showed that increased bone marrow blast count, HOXA9 mRNA, SE-CAD and PCⅢ levels were independent risk factors affecting the efficacy of chemotherapy in AML patients (all P < 0.05). ROC curves showed that the combination of HOXA9 mRNA, SE-CAD and PCIII could effectively predict the prognosis of AML patients, with a sensitivity of 84.80% and a specificity of 88.20%.DCAG regimen can significantly improve the levels of HOXA9 mRNA, SE-CAD and PCⅢ in AML patients, these three indicators are all independent risk factors affecting the prognosis of AML patients, and the combination of the three indicators can effectively predict the prognosis of the patients.